trial

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

NCTId NCT00222235
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 240
Sponsored by University of Maryland, Baltimore County
Primary completion 2004-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
240
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2000-01
Primary completion
2004-06
Eligibility
ALL · 18 Years · 54 Years

Interventions & indications

Drugs
d-cycloserineglycine

Sponsors

University of Maryland, Baltimore CountyLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
The Zucker Hillside HospitalCollaborator
Nathan Kline Institute for Psychiatric ResearchCollaborator
University of California Riverside at C.I. Trials, Inc.-Inland EmpireCollaborator
Sarah Herzog HospitalCollaborator
University of Maryland, Baltimore CountyCollaborator

Investigators

1
William T Carpenter, MDStudy Chair

Sites

5 total
Los Angeles, United StatesBaltimore, United StatesGlen Oaks, United StatesOrangeburg, United StatesJerusalem, Israel

Linked catalysts

1
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia — primary completion2004-06

Facts & assertions

4 sourced
Enrollment
240
Phase
PHASE2,PHASE3
Primary Completion Date
2004-06
Status
COMPLETED
relationships
The graph out of here
drug
d-cycloserine
drug
glycine
drug
lead_sponsor
University of Maryland, Baltimore County
company
collaborator
National Institute of Mental Health (NIMH)
company
The Zucker Hillside Hospital
company
indication
Schizoaffective Disorder
indication
Cognitive Dysfunction
indication
Schizophrenia
indication
investigator
William T Carpenter, MD
person